RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GW Pharmaceuticals Stock

GW Pharmaceuticals ROCE 2025

GW Pharmaceuticals ROCE

0

Ticker

GWPH

ISIN

US36197T1034

WKN

A1T980

In 2025, GW Pharmaceuticals's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

GW Pharmaceuticals Aktienanalyse

What does GW Pharmaceuticals do?

GW Pharmaceuticals PLC is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is a global leader in the research of medical cannabis and is headquartered in Cambridge. The history of GW Pharmaceuticals traces back to the founding of the company by Dr. Geoffrey Guy, who focused on the medical use of cannabis. In its early years, the company focused on developing medicinal cannabis strains with high levels of cannabinoids, such as THC or CBD. A pivotal moment for the company was the approval of Sativex in 2010, a medication for the treatment of spastic symptoms in multiple sclerosis. This was the first cannabis-based medication to be approved by a regulatory authority. Since then, GW Pharmaceuticals has expanded its portfolio of products and is involved in various areas, including the treatment of epilepsy, autism, pain, insomnia, and cancer. The company has several medications in late-stage clinical development and plans to bring more medications to the market. GW Pharmaceuticals' business model is based on researching, manufacturing, and selling medical cannabis. The company is an innovative pioneer in this field and works closely with health authorities and medical professionals to ensure the safety and efficacy of its products. GW Pharmaceuticals operates in several sectors, including the development of medical cannabis, the manufacturing of medications, and collaboration with health authorities and medical professionals. The company strives to develop high-quality and safe products that improve patients' quality of life. One of GW Pharmaceuticals' key products is Epidiolex, a medication for the treatment of severe forms of epilepsy in children. The medication contains CBD, one of the compounds found in medical cannabis, and has been approved by the U.S. Food and Drug Administration (FDA). Another important product of GW Pharmaceuticals is Sativex, a spray for the treatment of spastic symptoms in multiple sclerosis. The medication contains a combination of THC and CBD and is approved in several countries. GW Pharmaceuticals also has products in the pipeline targeting the treatment of autism, pain, insomnia, and cancer. The company is committed to advancing the use of medical cannabis and its compounds in medical practice and contributing to the improvement of health. Overall, GW Pharmaceuticals has made a significant contribution to the research and development of medical cannabis and has established itself as a leader in this field. The company is dedicated to developing high-quality medications that improve patients' lives and contribute to improving health. GW Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling GW Pharmaceuticals's Return on Capital Employed (ROCE)

GW Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing GW Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

GW Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in GW Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about GW Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of GW Pharmaceuticals this year?

The ROCE of GW Pharmaceuticals is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of GW Pharmaceuticals developed compared to the previous year?

The ROCE of GW Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of GW Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that GW Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of GW Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that GW Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from GW Pharmaceuticals impact the company?

An increase in the ROCE of GW Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of GW Pharmaceuticals affect the company?

A decrease in ROCE of GW Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of GW Pharmaceuticals?

Some factors that can affect GW Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of GW Pharmaceuticals so important for investors?

The ROCE of GW Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can GW Pharmaceuticals take to improve the ROCE?

To improve the ROCE, GW Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does GW Pharmaceuticals pay?

Over the past 12 months, GW Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GW Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of GW Pharmaceuticals?

The current dividend yield of GW Pharmaceuticals is .

When does GW Pharmaceuticals pay dividends?

GW Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GW Pharmaceuticals?

GW Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of GW Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GW Pharmaceuticals located?

GW Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GW Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GW Pharmaceuticals from 3/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/6/2025.

When did GW Pharmaceuticals pay the last dividend?

The last dividend was paid out on 3/6/2025.

What was the dividend of GW Pharmaceuticals in the year 2024?

In the year 2024, GW Pharmaceuticals distributed 0 USD as dividends.

In which currency does GW Pharmaceuticals pay out the dividend?

The dividends of GW Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GW Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von GW Pharmaceuticals

Our stock analysis for GW Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GW Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.